ESTRO Multidisciplinary Management of Breast Cancer 2017

Ongoing Trials for ductal carcinoma in situ

Study name

Study design

Main patient inclusion criteria

Aimed number of patients

Recruit- ment

Randomizes between active surveillance versus surgery ± RT ± Tamoxifen Yearly mammography Randomizes between active surveillance versus surgery ± RT ± Tamoxifen Yearly mammography Neoadjuvant treatment with letrozol for 6 month with MRT controls at 3 and 6 month Resection in case of progression

Female, > 46 years; screen detected or incidental microcalcification (unilateral or bilateral); Nonhigh-grade DCIS confirmed by local pathologist on either small volume core biopsy or VACB Woman of age ≥45 years, Calcifications only lesions, detected by population-based or opportunistic screening mammography; Representative vacuum-assisted core biopsy with pure low-grade DCIS

932

Since June 2014

LORIS (UK)

1240

Since December 2015

LORD (EORTC)

DCIS without invasive cancer or with microinvasion on diagnostic core biopsy; Estrogen and/or progesterone receptor positive; postmenopausal patient

115

Since February 2012

CALGB 40903